B. Riley Cuts Lantheus (NASDAQ:LNTH) Price Target to $122.00

Lantheus (NASDAQ:LNTH) had its target price cut by B. Riley from $127.00 to $122.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock. B. Riley also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS.

Other equities research analysts have also issued research reports about the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $129.43.

Lantheus Stock Down 1.2 %

Shares of LNTH stock opened at $97.71 on Friday. The stock has a market capitalization of $6.69 billion, a PE ratio of 16.26 and a beta of 0.38. Lantheus has a 52-week low of $57.92 and a 52-week high of $126.89. The stock’s 50-day moving average price is $92.67 and its 200 day moving average price is $96.51.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Analysts expect that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Atria Investments Inc acquired a new stake in shares of Lantheus during the 3rd quarter worth $330,000. Victory Capital Management Inc. increased its holdings in shares of Lantheus by 198.9% during the 3rd quarter. Victory Capital Management Inc. now owns 76,833 shares of the medical equipment provider’s stock worth $8,432,000 after buying an additional 51,128 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Lantheus during the 3rd quarter worth $222,000. Natixis Advisors LLC increased its holdings in shares of Lantheus by 8.2% during the 3rd quarter. Natixis Advisors LLC now owns 46,445 shares of the medical equipment provider’s stock worth $5,097,000 after buying an additional 3,516 shares during the last quarter. Finally, Swiss National Bank increased its holdings in shares of Lantheus by 0.4% during the 3rd quarter. Swiss National Bank now owns 135,354 shares of the medical equipment provider’s stock worth $14,855,000 after buying an additional 500 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.